Newsletter 24/2025
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! Holidays are in the air, but we still have something new for you this week! Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. […]
Cholesterol Identified as Key Shield in Heat-Resistant Cancer Cells
/0 Comments/in Hyperthermia, Preclinical Research/by MaxATRN-119: A New Promising ATR Inhibitor for ATM Mutations (And Other HRR Mutations)
/0 Comments/in Not PCa related/by MaxUPDATE: OncoACP3 Moving to Phase 1 Trial as Therapeutic Agent
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxSn-117m-DTPA Emerges as Theranostic: Phase 1/2 Trials
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxNewsletter 23/2025
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! For biology discovery enthusiasts (and AI applications) like me, last week was really exciting! But we also have good news on the clinical trial front! Stay strong and fight on! As usual, we also have a podcast if you […]
Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxUPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data talazoparib theranostics
Latest Posts
- Breakthrough in Cancer Immunotherapy: In Situ CAR-T Cell Generation Offers Hope for Lymphoma and Beyond July 17, 2025
- How Exercise Boosts Cancer Immunotherapy: The Role of Gut Microbes and Formate July 14, 2025
- Triplet therapy shows strongest survival benefit in mHSPC with visceral disease July 14, 2025
- Newsletter 28/2025 July 13, 2025